A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection

Trial Profile

A phase II, open-label, multi-center study to assess pharmacokinetics (PK), safety and efficacy of POL7080 co-administered with standard of care (SoC) treatment in patients with ventilator- associated pneumonia (VAP) due to suspected or documented Pseudomonas aeruginosa infection

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs Murepavadin (Primary)
  • Indications Nosocomial pneumonia; Pseudomonal infections
  • Focus Pharmacokinetics
  • Sponsors Polyphor
  • Most Recent Events

    • 25 Apr 2017 Results assessing PK and efficacy, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 16 Jun 2016 Status changed from completed to discontinued.
    • 12 Apr 2016 Interim results (n=10) presented at the 26th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top